Recently completed clinical study is informing the design of a large, global PMM clinical trial, which is planned to begin early 2021; summary to be presented at UMDF Power Surge 2020 SAN DIEGO, June 23, 2020 – Reneo Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development… Continue reading Reneo Pharmaceuticals Completes Clinical Study in Primary Mitochondrial Myopathies and Receives FDA Orphan Drug Designation for REN001
